60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 74-75

Background

While studies have reported that members of racial and minority populations hospitalized with metastatic breast cancer (MBC) have lower palliative care use than non-Hispanic White women, disparities in hospital-associated outcomes among inpatients have not been explored in this population. We examined the racial disparities in hospitalization outcomes among adult women with a diagnosis of MBC, stratified by receipt of palliative care.

Methods

Retrospective cohort analyses were conducted using the Agency for Healthcare Research and Quality (AHRQ)–sponsored Healthcare Cost and Utilization Project, National Inpatient Sample (HCUP–NIS) database from 2016 to 2020. Multivariable logistic and linear regression models were used to examine the association between race/ethnicity and in-hospital mortality, length of stay, and total hospital charges. Multinomial logistic regression models were used to evaluate the association between race/ethnicity and discharge disposition. Stratified analyses were conducted by palliative care use. Results were reported as adjusted odds ratios (AOR).

Results

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

In the adjusted analyses, Black (AOR, 1.25; 95% CI, 1.16-1.34), Hispanic (AOR, 1.12; 95% CI, 1.01-1.23), and other (AOR, 1.26; 95% CI, 1.12-1.40) MBC patients had higher in-hospital mortality compared to the White patients. After stratifying by palliative care use, Black women who received palliative care had similar odds (AOR, 1.08; 95% CI, 0.97-1.20) of in-hospital mortality while those without palliative care use had 46% higher odds (95% CI, 1.30-1.64) of mortality when compared to White women. Black women were more likely (AOR, 1.18; 95% CI, 1.13-1.23) to have a length of stay greater than 5 days compared to 5 days or less relative to White women. Furthermore, Black, Hispanic, and other women had higher total hospital charges when compared with patients who are White. While women who were Black had similar odds (AOR, 0.98; 95% CI, 0.92-1.04) of being discharged to a short-term/skilled nursing facility vs routine discharge compared with women who were White, women who were Black who received palliative care had 19% (95% CI, 0.70-0.95) lower odds of being discharged to a facility. Hispanic and other MBC patients were less likely to be discharged to a facility relative to routine discharge when compared with women who were White.

Conclusions

Despite the improvement in palliative care use over the years, members of racial minority populations continue to have poorer outcomes. However, patients who are Black with MBC who received palliative care had similar in-hospital mortality and were less likely to be discharged to a facility when compared with their White counterparts. Our findings emphasize the importance of palliative care use among MBC patients and highlight the need to continue to raise awareness of its benefits, especially in minority populations. Further studies are needed to explore ways to narrow the gap in existing disparities and to test these interventions on care metrics and patient outcomes.

Articles in this issue

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
64 Empowering Medical Students to Deliver Breast Health Education:  A Community-Based Initiative
64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the  PREDICT Study
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table